Vol 5, No 4 (2020)
Original article
Published online: 2020-11-20
The rationale for Multilevel Educational and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION) project is to support multicentre randomized clinical trial Evaluating Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA – SIRIO 2)
1
, 2, 3, 4, 5, 6, 7, 2, 58, 9, 1, 6, 5, 10, 7, 4, 2
, 2, 3, 4, 5, 6, 7, 2, 58, 9, 1, 6, 5, 10, 7, 4, 2
Medical Research Journal 2020;5(4):244-249.
Abstract
The Multilevel Educational and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION) project will be adopted to support adherence to the study treatment in the Evaluation Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA-SIRIO 2) a randomized clinical trial.
A prespecified sub-analysis of the ELECTRA-SIRIO 2 trial will be performed to evaluate the impact of the results of MEDMOTION diagnostic questionnaires on the clinical outcomes.
The study population will comprise of 4,500 patients consecutively admitted to the study centres due to acute coronary syndrome. The MEDMOTION project involves the following interventions: patients’ education, motivation, reminding to take medications and to attend consecutive medical appointments. Dedicated questionnaires will be applied to diagnose study participants with regard to their readiness for discharge from the hospital at the end of initial hospitalization, the risk of non-adherence to the medication at the end of 3rd and 12th month of follow up, and the functioning in disease at the end of 3rd and 12th month of follow up. The primary safety composite endpoint of this study is type 2, 3 or 5 bleeding according to the BARC criteria, occurring during the first 12 months after ACS. The primary efficacy endpoint is the composite of death from any cause, the first nonfatal MI, or the first nonfatal stroke. The key secondary endpoint, net clinical effect, was defined as the composite of death from any cause, a nonfatal MI or a nonfatal stroke, and the first occurrence of BARC type 2, 3, or 5 bleeding.
Concluding, it is expected that the comprehensive approach designed in the MEDMOTION project, including use of diagnostic questionnaires, will significantly contribute to obtaining a high level of adherence to medication and improving clinical outcomes in the ELECTRA-SIRIO 2 trial.
Keywords: acute coronary syndromeadherence to medicationfunctioning in chronic illnessticagrelorantiplatelet treatment
References
- Barrett. Tx. World Health Organization. Adherence to long-term therapies: evidence for action. http://www.who.int/chp/knowledge/publications/adherence_full_report.pd.
- Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333(7557): 15.
- Kubica J, Adamski P, Buszko K, et al. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. Eur Heart J Cardiovasc Pharmacother. 2018; 4(3): 152–157.
- Winter MP, Grove EL, De Caterina R, et al. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother. 2017; 3(4): 221–234.
- Winter MP, Koziński M, Kubica J, et al. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej. 2015; 11(4): 259–280.
- Stewart K, Mc Namara KP, George J. Challenges in measuring medication adherence: experiences from a controlled trial. Int J Clin Pharm. 2014; 36(1): 15–19.
- Kubica A, Sinkiewicz W, Szymański P, et al. Edukacja zdrowotna w chorobach układu krążenia - możliwości i zagrożenia. Folia Cardiologica Excerpta. 2007; 2: 177.
- Kubica A. Wybrane problemy prewencji wtórnej u chorych po incydentach wieńcowych. Folia Cardiologica Excerpta. 2008; 3: 366.
- Kubica A, Obońska K, Kasprzak M, et al. The impact of metabolic syndrome on the antiplatelet effect of clopidogrel and aspirin in patients with acute coronary syndrome. : Folia Med Copernicana. 2014; 2: 66–72.
- Kubica A, Kasprzak M, Obońska K, et al. Impact of health education on adherence to clopidogrel and clinical effectiveness of antiplatelet treatment in patients after myocardial infarction: Folia Med. Copernicana. 2015; 3: 154–159.
- Kubica J, Jaguszewski M. ISAR-REACT 5 - What have we learned? Cardiol J. 2019; 26(5): 427–428.
- Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
- Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001; 26(5): 331–342.
- Zhao S, Zhao H, Wang L, et al. Education is critical for medication adherence in patients with coronary heart disease. Acta Cardiol. 2015; 70(2): 197–204.
- Polack J, Jorgenson D, Robertson P. Evaluation of different methods of providing medication-related education to patients following myocardial infarction. Canadian Pharmacists Journal. 2008; 141(4): 241–247.
- Kubica A, Pufal J, Moczulska B, et al. Skuteczność edukacji zdrowotnej u osób hospitalizowanych w klinice kardiologii. Psychiatria w Praktyce Ogólnolekarskiej. 2005; 5: 61.
- Kubica A. Problems of long-term antiplatelet therapy after coronary stent implantation. Advances in Interventional Cardiology. 2009; 5: 158–161.
- Kubica A, Grześk G, Sinkiewicz W, et al. Compliance, concordance, adherence in chronic therapy. Folia Cardiol Excerpta. 2010; 5: 54–57.
- Buszko K, Obońska K, Michalski P, et al. The Adherence Scale in Chronic Diseases (ASCD). The power of knowledge: the key to successful patient — health care provider cooperation. Medical Research Journal. 2016; 1(1): 37–42.
- Kosobucka A, Michalski P, Pietrzykowski Ł, et al. Adherence to treatment assessed with the Adherence in Chronic Diseases Scale in patients after myocardial infarction. Patient Prefer Adherence. 2018; 12: 333–340.
- Kosobucka A, Michalski P, Pietrzykowski Ł, et al. The impact of readiness to discharge from hospital on adherence to treatment in patients after myocardial infarction. Cardiol J. 2020 [Epub ahead of print].
- Pietrzykowski Ł, Michalski P, Kosobucka A, et al. Medication adherence and its determinants in patients after myocardial infarction. Sci Rep. 2020; 10(1): 12028.
- Kubica A, Kosobucka A, Michalski P, et al. The Adherence in Chronic Diseases Scale — a new tool to monitor implementation of a treatment plan. Folia Cardiologica 2017;12:19-26, DOI: 10. 5603/FC. ; 2016: 0000.
- Kubica A, Kochman W, Bogdan M, et al. The influence of undergone percutaneous coronary interventions, and earlier hospitalizations with myocardial infarction on the level of knowledge and the effectiveness of health education in patients with myocardial infarction. Advances in Interventional Cardiology. 2009; 5: 25–30.
- DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004; 42(3): 200–209.
- Tang L, Patao C, Chuang J, et al. Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010). Am J Cardiol. 2013; 112(8): 1126–1132.
- Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
- Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014; 742: 47–54.
- Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol. 2016; 74(1): 61–67.
- Wang PS, Benner JS, Glynn RJ, et al. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf. 2004; 13(1): 11–19.
- Frost MH, Reeve BB, Liepa AM, et al. Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group;. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health. 2007; 10 Suppl 2: S94–S9S105.
- Krousel-Wood M, Muntner P, Jannu A, et al. Reliability of a medication adherence measure in an outpatient setting. Am J Med Sci. 2005; 330: 128–133.
- Kubica A. Collaboration with the patient - a basic condition of therapy effectiveness in coronary artery disease. Chor. Serca Nacz. 2009; 6: 131–134.
- Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166(17): 1842–1847.
- Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213–260.
- Kubica J, Adamski P, Niezgoda P, et al. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020 [Epub ahead of print].
- Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother. 2016; 17(17): 2291–2306.
- Kubica A. Self-reported questionnaires for a comprehensive assessment of patients after acute coronary syndrome. Medical Research Journal. 2019; 4(2): 106–109.
- Michalski P, Kasprzak M, Siedlaczek M, et al. The impact of knowledge and effectiveness of educational intervention on readiness for hospital discharge and adherence to therapeutic recommendations in patients with acute coronary syndrome. Medical Research Journal. 2020.
- Kubica A. Rationale of cardiopulmonary resuscitation training as an element of multilevel educational and motivational project (MEDMOTION). Disaster and Emergency Medicine Journal. 2020.
- Kubica A, Bączkowska A. Uzasadnienie interwencji motywacyjnych jako kluczowego elementu projektu wielopoziomowej edukacji i motywacji u pacjentów z zawałem serca (MEDMOTION). Folia Cardiologica. 2020; 15(1): 6–10.
- Buszko K, Pietrzykowski Ł, Michalski P, et al. Validation of the Functioning in Chronic Illness Scale (FCIS). Medical Research Journal. 2018; 3(2): 63–69.
- Pietrzykowski Ł, Michalski P, Kosobucka A, et al. Knowledge about health and disease in obese patients after myocardial infarction. An observational study. Medical Research Journal. 2018; 2(4): 135–140.
- Kubica A, Kosobucka A, Michalski P, et al. Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases. Medical Research Journal. 2018; 2(4): 115–122.
- Kubica A, Gruchała M, Jaguszewski M, et al. Adherence to treatment — a pivotal issue in long-term treatment of patients with cardiovascular diseases. An expert standpoint. Medical Research Journal 2017;2(4):123-127. DOI: 10 5603/MRJ. ; 2017: 0016.
- Kosobucka A, Kasprzak M, Michalski P, et al. Relation of the Readiness for Hospital Discharge after Myocardial Infarction Scale to socio-demographic and clinical factors. An observational study. Medical Research Journal 2018;3(1):32-37. DOI: 10 5603/MRJ. ; 2018: 0006.
- Michalski P, Kosobucka A, Pietrzykowski Ł, et al. Effectiveness of therapeutic education in patients with myocardial infarction. Medical Research Journal. 2018; 2(3): 89–96.
- Buszko K, Kosobucka A, Michalski P, et al. The readiness for hospital discharge of patients after acute myocardial infarction: a new self-reported questionnaire. Medical Research Journal. 2017; 2(1): 20–28.
- Miller WR. Motivational interviewing with problem drinkers. Be- havioural Psychotherapy. 2009; 11(2): 147–172, doi: 10. ; 1017: s0141347300006583.
- Miller W, Rollnick S. Motivational Interviewing: Preparing People for Change, 2nd ed. Journal For Healthcare Quality. 2003; 25(3): 46.
- Hardcastle S, Taylor A, Bailey M, et al. A randomised controlled trial on the effectiveness of a primary health care based counselling intervention on physical activity, diet and CHD risk factors. Patient Educ Couns. 2008; 70(1): 31–39.
- Hardcastle SJ, Taylor AH, Bailey MP, et al. Effectiveness of a motivational interviewing intervention on weight loss, physical activity and cardiovascular disease risk factors: a randomised controlled trial with a 12-month post-intervention follow-up. Int J Behav Nutr Phys Act. 2013; 10: 40.
- Garbers S, Hunersen K, Nechitilo M, et al. Healthy Weight and Cardiovascular Health Promotion Interventions for Adolescent and Young Adult Males of Color: A Systematic Review. Am J Mens Health. 2018; 12(5): 1328–1351.
- Gianos E, Schoenthaler A, et al. Guo Yu, Investigation of motivational interviewing and prevention consults to achieve cardiovascular tar- gets (IMPACT) trial. Am Heart J. 2018; 199: 37–43, doi: 10.1016/j. ahj.2017.12. 019, indexed in Pubmed. ; 29754664.
- Ringen PA, Falk RS, Antonsen B, et al. Using motivational techniques to reduce cardiometabolic risk factors in long term psychiatric inpatients: a naturalistic interventional study. BMC Psychiatry. 2018; 18(1): 255.
- Heckman CJ, Egleston BL, Hofmann MT. Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. Tob Control. 2010; 19(5): 410–416.
- Dobber J, Latour C, de Haan L, et al. Medication adherence in patients with schizophrenia: a qualitative study of the patient process in motivational interviewing. BMC Psychiatry. 2018; 18(1): 135.
- Miller WR, Rollnick S. Motivational Interviewing: preparing people for change. 2nd ed. Guilford Press, New York. ; 2002.